Double Marker First‑Trimester Prenatal Screening Guidelines

Indications and Universal Offer

• All pregnant individuals should be offered first‑trimester screening for chromosomal abnormalities early in pregnancy, irrespective of maternal age or baseline risk. 1

Timing and Sample Collection

• The double‑marker test is performed between 11 – 13 weeks gestation, with 12 weeks being optimal when combined with nuchal‑translucency (NT) ultrasound. 2
• Free β‑hCG yields a 2‑3 % higher detection rate when measured at 11‑12 weeks, whereas intact hCG shows a modest 1‑2 % advantage at 13 weeks. 2

Test Components and Expected Biochemical Patterns

• Pregnancy‑associated plasma protein‑A (PAPP‑A) concentrations are typically reduced in pregnancies affected by trisomy 21. 2
• Free β‑hCG concentrations are typically elevated in pregnancies affected by trisomy 21. 2

Risk Calculation and Thresholds

• A screen‑positive result is defined by a calculated risk of ≥ 1:250 (or 1:300) for trisomy 21. [3][4]

Interpretation of Results

• Positive screen – Recommend genetic counseling and offer diagnostic testing (chorionic‑villus sampling or amniocentesis). 2
• Negative screen – Provides reassurance but does not eliminate residual risk for chromosomal abnormalities. 3

Performance Characteristics

• The traditional first‑trimester combined screening has a positive predictive value (PPV) of ~3.6 %, requiring about 28 invasive diagnostic procedures to confirm one case of trisomy 21; second‑trimester screening requires 28‑45 procedures. [3][4]
• Cell‑free DNA (NIPS) achieves a PPV of 50‑95 % for trisomy 21, reducing the number of required diagnostic procedures to 1‑2 per confirmed case. [3][4]

Integration with Nuchal‑Translucency Ultrasound

• Adding NT measurement to the double‑marker test (forming the “combined first‑trimester screening”) increases detection rates by roughly 20‑25 % compared with NT alone. 2

Comparison with Alternative Screening Modalities

• Double‑marker screening yields earlier results than the second‑trimester quad screen (performed at 15‑20 weeks), allowing earlier decision‑making and the option of first‑trimester CVS if diagnostic testing is pursued.
• Although cell‑free DNA testing offers superior detection and PPV, it is more costly; the double‑marker test remains a widely used, cost‑effective option. [3][5]

Special Populations

• Twin pregnancies – Serum marker levels represent an average of both fetuses, reducing accuracy; NT measurement alone is more informative, and specialized algorithms are required rather than singleton cutoffs. 2
• Maternal risk factors – Obesity, autoimmune disorders, and certain anticoagulant therapies can affect test performance and should be discussed during counseling. 3

Clinical Management Recommendations

• Offer diagnostic testing to individuals aged ≥ 35 years in addition to screening, acknowledging the higher baseline risk.
• Ensure accurate gestational dating using ultrasound crown‑rump length rather than relying on hCG levels. (Technical recommendation derived from guideline context.)

All statements are supported by the cited references and reflect current guideline recommendations.

Prenatal Screening for Down Syndrome and Other Aneuploidies

Introduction to Screening Tests

• The American College of Medical Genetics recommends that multiple marker screening (AFP, hCG, uE3 with or without INH-A) should be offered to all women, unless amniocentesis is already indicated or first trimester screening was performed 6, 7, 8

Screening Test Components and Detection Rates

• The enhanced quadruple marker test detects approximately 75-80% of Down syndrome cases, compared to the dual marker's lower detection rate 6, 7
• The quadruple marker test (adds Inhibin A) detects approximately 75% in women under 35 and over 80% in women 35 and older 6, 9
• Alpha-fetoprotein (AFP) primarily screens for neural tube defects, with a detection rate of 75-90% for open neural tube defects and 95% for anencephaly 10, 11

Clinical Implementation and Interpretation

• The optimal testing window for both tests is 16-18 weeks gestation, with an acceptable range of 15-20 weeks, requiring accurate gestational age documentation 6, 10, 11, 8
• Risk calculation adjustments are required for maternal weight, race, insulin-dependent diabetes, number of fetuses, and family history of neural tube defects 10, 11

Guideline Recommendations and Common Pitfalls

• The American College of Medical Genetics position is that women 35 and older should still be offered CVS and amniocentesis for definitive diagnosis 6, 7
• Technical errors to avoid include failing to use ultrasound dating, not reinterpreting with revised dates, and using singleton cutoffs for twins 6, 10, 11
• Clinical management errors to avoid include inadequate counseling, not offering follow-up, and ignoring maternal factors 6, 7, 10, 11, 8